Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Autoimmunity. 2014 Nov 20;48(4):222–230. doi: 10.3109/08916934.2014.984836

Figure 1.

Figure 1

Acthar ameliorates EAE. SJL/J female mice were immunized with PLP139-151 peptide in CFA. (A) Upon relapse, at day 24 (start of 2nd attack, break in line), the mice were grouped by clinical score and treated with Acthar or Placebo gel (starting on day 25) every other day or untreated between days 25 and 46. (B) Upon relapse (start of 2nd attack on day 26), with a clinical score of ≥1 for 2 consecutive days, day 30 (break in line), the mice were treated with Acthar or Placebo gel (starting on day 31) every other day or untreated between days 31 and 43. Data represent mean clinical score ± standard error of the mean (SEM). Analysis of clinical scores can be found in Tables 1 and 2. *p<0.05, t test.